DNTH Overview

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is77.00 USD with a low forecast of 46.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Dianthus Therapeutics Inc revenue for the last quarter amounts to 284.00K USD, decreased -78.58

Dianthus Therapeutics Inc. EPS for the last quarter amounts to -1.43 USD, increased 78.75

Dianthus Therapeutics Inc (DNTH) has 92 emplpoyees as of March 12 2026.

Today DNTH has the market capitalization of 3.82B USD.